ReviewBiomedicines2023
Adipokines in Rheumatoid Arthritis: Emerging Biomarkers and Therapeutic Targets.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Serum visfatin level and subfoveal choroidal thickness as independent associates of radiographic ankylosing spondylitis: a case-control study.Rheumatology international · 2026Article
- Differential Expression of Visfatin, Sirtuin-1, and Interleukin-18 in Ankylosing Spondylitis Patients: A Comparative Study of Etanercept-Treated versus Newly Diagnosed Patients.Iranian journal of medical sciences · 2026Article
- Cellular crosstalk and signaling networks in the rheumatoid arthritis synovial microenvironment.Journal of translational medicine · 2026Review
- Article
- Sarcopenia and sarcopenic obesity in rheumatoid arthritis patients: prevalence and their relationship with joint damage and functional impairment.Osteoporosis and sarcopenia · 2025Article
- Functional Roles of the Complement Immune System in Cardiac Inflammation and Hypertrophy.International journal of molecular sciences · 2025Review
- Editorial for the Special Issue: Feature Reviews in Adipokines.Biomedicines · 2025Article
- Evaluating the Causal Relationship Between Human Blood Metabolites and the Susceptibility to Alopecia Areata.Journal of cosmetic dermatology · 2025Article
- In early rheumatoid arthritis, comorbidities do not explain the increased risk of failure to reach remission in patients with obesity.RMD open · 2025Article
- GPIHBP1 increase accounts for rheumatic arthritis-related hypotriglyceridemia by facilitating lipids uptake of white adipose tissues.Arthritis research & therapy · 2025Article
- Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis.ACR open rheumatology · 2025Article
- Association between relative fat mass and risk of arthritis: a study based on populations in China and the United States.Frontiers in nutrition · 2025Article
- Study of adiponectin gene (rs1501299) polymorphism and serum adiponectin level in patients with primary knee osteoarthritis.Human genomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease manifested by joint involvement, extra-articular manifestations, and general symptoms. Adipose tissue, previously perceived as an inert energy storage organ, has been recognised as a significant contributor to RA pathophysiology. Adipokines modulate immune responses, inflammation, and metabolic pathways in RA. Although most adipokines have a pro-inflammatory and aggravating effect on RA, some could counteract this pathological process. The coexistence of RA and sarcopenic obesity (SO) has gained attention due to its impact on disease severity and outcomes. Sarcopenic obesity further contributes to the inflammatory milieu and metabolic disturbances. Recent research has highlighted the intricate crosstalk between adipose tissue and skeletal muscle, suggesting potential interactions between these tissues in RA. This review summarizes the roles of adipokines in RA, particularly in inflammation, immune modulation, and joint destruction. In addition, it explores the emerging role of adipomyokines, specifically irisin and myostatin, in the pathogenesis of RA and their potential as therapeutic targets. We discuss the therapeutic implications of targeting adipokines and adipomyokines in RA management and highlight the challenges and future directions for research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.